Liposomal formulation of amphiphilic fullerene antioxidants by Dellinger, Anthony et al.
Liposomal formulation of amphiphilic fullerene antioxidants 
 
By: Zhiguo Zhou, Robert P. Lenk, Anthony Dellinger, Stephen R. Wilson, Robert Sadler, and 
Christopher L. Kepley 
 
Zhou Z, Lenk RP, Dellinger A, Wilson SR, Sadler R, Kepley, CL. Liposomal formulation of 
amphiphilic fullerene antioxidants. Bioconjugate Chemistry. 2010; 21:1656-61. 
 
This document is the Accepted Manuscript version of a Published Work that appeared in 
final form in Bioconjugate Chemistry, copyright © American Chemical Society after peer 
review and technical editing by the publisher. To access the final edited and published 
work see https://doi.org/10.1021/bc1001664 
 
***© 2010 American Chemical Society. Reprinted with permission. No further 
reproduction is authorized without written permission from American Chemical Society. 
This version of the document is not the version of record. Figures and/or pictures may be 
missing from this format of the document. *** 
 
Abstract: 
 
Novel amphiphilic fullerene[70] derivatives that are rationally designed to intercalate in lipid 
bilayers are reported, as well as its vesicular formulation with surprisingly high loading capacity 
up to 65% by weight. The amphiphilic C70 bisadduct forms uniform and dimensionally stable 
liposomes with auxiliary natural phospholipids as demonstrated by buoyant density test, particle 
size distribution, and 31P NMR. The antioxidant property of fullerenes is retained in the bipolarly 
functionalized C70 derivative, amphiphilic liposomal malonylfullerene[70] (ALM), as well as in 
its liposomal formulations, as shown by both electron paramagnetic resonance (EPR) studies and 
in vitro reactive oxygen species (ROS) inhibition experiments. The liposomally formulated ALM 
efficiently quenched hydroxyl radicals and superoxide radicals. In addition, the fullerene 
liposome inhibited radical-induced lipid peroxidation and maintained the integrity of the lipid 
bilayer structure. This new class of liposomally formulated, amphipathic fullerene compounds 
represents a novel drug delivery system for fullerenes and provides a promising pathway to treat 
oxidative stress-related diseases. 
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Article: 
 
Introduction 
 
Fullerenes and their derivatives have been proposed as free radical scavengers (1), and a number 
of investigations have studied fullerene (C60) derivatives as potential free radical antioxidant 
therapeutics (2-5). Fullerenes (both pristine and derivatized fullerenes) have a tendency toward 
aggregation in aqueous environments making them unsuitable for therapeutic applications. For 
example, formulation techniques for preparing fullerene-based therapeutic candidates include 
host−guest complexation with cyclodextrins and calixerenes, surfactant solubilization with 
Tween-20 and polyvinylpyrrolidone (PVP), and so forth. These preparations have their 
respective limitations in terms of uniformity of formulation, loading capacity, aggregation, and 
partition coefficient (5). Derivatization of fullerenes by directly adding moieties to the carbon 
cage has been used as a strategy to produce useful drug candidates. Such fullerene compounds 
including polyhydroxylated C60 (fullerenol) (6, 7), polysulfonated C60 (8), and carboxylated 
fullerenes (9, 10) have been shown to block free radical damages in several oxidative stress-
related diseases including ischemia/reperfusion injury, inflammatory apoptosis, and 
neurogenerative diseases. However, aggregation in aqueous media to form particles with a broad 
range of diameter distributions is a general problem for many of those compounds (11). 
Polyderivatized fullerenes are often a mixture of many compounds, poorly characterized and not 
suitable for pharmaceutical development. In addition, it has been shown that cytotoxicity of 
fullerenes is related to the degree of cage derivatization, water solubility, aggregation, and 
particle size (11). An alternative approach in which fullerenes are encapsulated in bilayer 
vesicles such as liposomes has been proposed to overcome these limitations. Bensasson 
described the preparation of vesicles by incorporating C60 into l-α-phophatidyl choline purified 
from egg yolk (Egg-PC) (12). However, the authors reported that only 3% or less C60 was 
incorporated in Egg-PC liposomes and the preparation was not uniformly reproducible. 
Incorporation of C60 into l-α-phophatidyl ethanolamine (PE) was limited to 7% (13). Fullerene 
liposomes have also been prepared by transferring fullerenes from their water-soluble host−guest 
complexes (C60·γ-CD and C70·γ-CD) to lipid membranes for photodynamic therapy (PDT) (14, 
15). The limited number of reports on liposomal fullerene formulations were all intended to use 
underivatized fullerenes that are not lipophilic, rather aromatic, and structurally incompatible 
with natural phospholipids; therefore, the fullerene contents were low and their dimensional 
stabilities were problematic. Further, the loading capacity of lipophilic drugs physically 
entrapped in the liposome bilayer is limited because of the membrane destabilization effect. 
Thus, it is necessary to develop new drug delivery strategies that can efficiently deliver 
fullerenes for therapeutic applications. 
 
Given the low contents of pristine fullerenes in liposomal formulations, we hypothesized that 
incorporating amphiphilic fullerenes in vesicles would greatly increase their ability to be 
intercalated within the lipid bilayers. Herein, we report the design and synthesis of this new class 
of amphiphilic fullerenes, their liposome formulation and biological activities as radical 
scavengers. A key to obtaining a uniform vesicular preparation with high fullerene content and 
dimensional stability is to incorporate amphiphilic fullerene derivatives which mimic the 
structure of natural phospholipids. Hirsch has reported amphiphilic C60 derivatives in which 
multiple aliphatic hydrocarbons were attached at various sites on the fullerene cage (16, 17). 
However, these “buckysomes” do not assemble into stable bilayers readily, and the addition of 
multiple groups could significantly damage their bioactivity. 
 
Figure 1 illustrates the design strategy in which the amphiphilic fullerenes and phospholipids are 
hypothesized to coassemble and form bilayer vesicles. As shown below, this method leads to 
highly increased loading capacity of fullerenes. The amphiphilic fullerene compounds do not 
form bilayer vesicles by themselves, but require membrane-forming lipids with lipid-to-fullerene 
molar ratio greater than 1:1 in order to produce uniform and dimensionally stable vesicles. We 
have also discovered that the oval structure of C70 molecule (as opposed to the spherical C60) 
provides a novel structural platform to prepare this new type of amphiphilic fullerenes. C70 has 
two reactive poles and a relatively inert equatorial region, and this allows for sequentially 
attaching lipophilic and hydrophilic groups at the two poles, respectively (18). The large 
underivatized zone around the C70 belt has very high radical reactivity due to the significant 
orbital overlap of its lowest unoccupied molecular orbital (LUMO) and highest occupied 
molecular orbital (HOMO) that is expected for sites of maximum radical reactivity (19-21). The 
fullerene-enriched liposome provides a novel formulation approach that not only enhances the 
fullerene delivery efficiency, but also maintain their antioxidative properties. 
 
 
Figure 1. Vesicle formation of amphiphilic fullerenes with auxiliary phospholipids. 
 
Materials and Methods 
 
Synthesis of C70 Monoadduct 2. To a stirred solution of C70 (84.0 mg, 0.1 mmol), 
didodeceylmalonate 1 (44.0 mg, 0.1 mmol) prepared using literature procedure (22), and iodine 
(25.4 mg, 0.1 mmol) in 60 mL of dry toluene was added dropwise a solution of DBU (38.0 mg, 
0.25 mmol) in 5 mL of dry toluene under nitrogen at room temperature. Upon completion of 
addition, the reaction mixture was stirred for an additional 3 h. The reaction mixture was then 
washed with brine and dried over anhydrous MgSO4. The raw mixture was subjected to flash 
chromatography on silica gel. Unreacted C70 was removed by eluting the column with a mixture 
of toluene and hexanes (60/40, v/v), and then, the eluant was changed to toluene/hexanes (90/10, 
v/v) to give the product 2 (108 mg, 85%). The undesirable bisadducts were eluted from the 
column with DCM. MALDI-MS: 1278.4, 1H NMR (CDCl3): δ 0.79 (6H, t), 1.20 (32H, m), 1.38 
(4H, m), 1.75 (4H, m), 4.37 (4H, t); 13C NMR (CDCl3) δ 14.5, 22.3, 25.8, 28.7, 29.1, 29.2, 29.3, 
29.8 (3×), 31.9, 37.2, 67.0, 130.7, 130.8, 130.9, 132.8, 133.6, 137.0, 140.7, 141.6, 142.2, 142.8, 
143.0, 143.5, 143.8, 143.9, 144.9, 145.9, 146.0, 146.5, 147.0, 147.3, 147.5, 147.6, 148.4, 148.5, 
148.6, 148.8, 149.1, 149.3, 149.4, 150.6, 150.8, 151.2, 151.3, 151.4, 155.1, 163.5. 
 
Synthesis of Di(tert-butylglycolate)malonate 3. To a stirred solution of malonic acid (1.04 g, 
10 mmol) in 60 mL 1,4-dioxane was added 2.78 mL of TEA (2.02 g, 20 mmol). The mixture was 
stirred for 15 min before tert-butyl bromoacetate (4.68 g, 24 mmol) was added dropwise. The 
resulting mixture was vigorously stirred for 2−3 days until the reaction was complete as 
monitored by TLC. The precipitates were then filtered and the filtrate was washed twice with 
brine, dried over MgSO4, and rotavaped in vacuo to give the pure di(tert-
butylglycolate)malonate 3 as a colorless oil (2.92 g, 88%). 1H NMR (CDCl3): δ ppm 1.39 (18H, 
s), 3.51 (2H, s), 4.49 (4H, s); 13C NMR (CDCl3) δ ppm 28.5, 40.2, 61.4, 82.3, 165.5, 167.3. 
 
Synthesis of ALM. To a stirred solution of monoadduct 2 (127.8 mg, 0.1 mmol), di(tert-
butylglycolate)malonate 3(33.2 mg, 0.1 mmol), and iodine (25.4 mg, 0.1 mmol) in 60 mL of dry 
toluene was dropwise added a solution of DBU (35.0 mg, 0.22 mmol) in 5 mL of dry toluene 
under nitrogen at room temperature. The resulting reaction mixture was stirred for 6 h. The 
reaction mixture was washed with brine and then dried over anhydrous MgSO4. The raw mixture 
was subjected to flash chromatography on silica gel. Unreacted monoadduct was removed by 
eluting the column with toluene, and then the eluant was changed to DCM to give the product 
(121 mg, 75%). MALDI-MS: 1608.2. 1H NMR (CDCl3): δ 0.75 (6H, m), 1.19 (32H, m), 1.38 
(4H, m), 1.43 (18H, s), 1.71 (4H, m), 4.39 (4H, m), 4.75 (4H, m). The product diester (80.0 mg) 
was dissolved in a mixture of 30 mL DCM and 9 mL TFA, and stirred for 2 h. The solvent was 
evaporated and dried under vacuum to quantitatively yield pure ALM. MALDI-MS: 1498.2 (see 
MALDI-MS spectra in Supporting Information), 1H NMR (DMSO): δ 0.79 (6H, m), 1.21 (32H, 
m), 1.39 (4H, m), 1.74 (4H, m), 4.40 (4H, m), 4.78 (4H, m). 
 
Liposome Preparation. Two parts (by weight) of egg-PC or other lipids such as DMPC and 
DSPC were added to one part amphipathic ALM in diethyl ether (1 mg/mL). The addition of 
lipids enhanced the solubility of ALM, although ALM itself has reasonable solubility in diethyl 
ether. The mixture was sonicated for 2 min before filtration via 0.2 μm filter. To the filtrate, an 
aqueous buffered solution (PBS, phosphate buffered saline, pH = 7.4) was added, and the two-
phase mixture was sonicated in a bath sonicator while purging with nitrogen to produce 
oligolamellar vesicles. Those oligolamellar vesicles were extruded with nucleopore membranes 
of 0.4, 0.2, and 0.1 μm, twice each pore size. The final ALM concentration in liposome 
suspensions was determined by UV−vis spectroscopy with a standard curve after extracting it to 
organic solvents. Size distribution of extruded liposomes was measured by dynamic light 
scattering (DLS) with Zetasizer nano S90. 
 
Inhibition of Lipid Peroxidation. Dye-encapsulated liposomes were prepared by adding a 
buffered solution of the dye HPTS (20 mM, pH = 6.6) to an ether solution of egg-PC lipids (1 
mg/mL) with or without ALM (1% by weight), purging nitrogen to remove ether in a bath 
ultrasonicator at room temperature, and extruding the crude liposomes with 400, 200, and 100 
nm nuclear-pore membranes twice each. Dye-encapsulated liposome materials were separated 
from free dyes by SEC (size exclusion chromatography) on a Sephadex G-50 column with a 
buffered solution (pH = 7.8) (23, 24). The final dye concentration was 0.2 mM as determined by 
its UV−vis absorption. The absorption spectrum of the purified dye-encapsulated liposome 
samples were taken before and after the addition of Fenton reagents, and the final concentrations 
of H2O2 and FeSO4 are 1 mM and 0.05 mM, respectively. Each scan was recorded at 30 min, 1 h, 
2 h, 4 h, 8 h, 16 h, 24 h, 32 h, and 48 h after the radical initiation. The absorbance ratio (A450 
nm/A405 nm) and absorbance difference (A450 nm − A405 nm) were plotted as a function of reaction 
time. 
 
EPR Experiments. EPR studies on radical quenching (hydroxyl radicals and superoxide 
radicals) were performed as described (25). Compound ALM was dissolved in dry DMSO at 1.0 
mg/mL (0.67 mM), and DMSO was run as a vesicle control. Hydroxyl radicals were generated 
using standard concentrations of Fe2+/H2O2 through Fenton reactions. Superoxide radical anions 
O2·− were generated through xanthine oxidase metabolism of hypoxanthine (HX/XO). EPR 
signals were acquired after 20 min incubation of ALM with radical-generating systems. 
 
Cellular ROS Inhibition. U937 monocyte cells obtained from ATCC (Manassas, VA) were 
cultured in RPMI-1640 media supplemented with 10% FBS (fetal bovine serum). Cells were 
pretreated with ALM liposome or control liposome or untreated overnight in a 37 °C incubator 
with 6% CO2, washed, and resuspended in RPMI medium containing 5 μM DCFH-DA (2′,7′-
dichlorodihydrofluorescein diacetate) at 37 °C for 30 min. After incubation, the cells were 
washed (to remove any excess DCFH-DA) and activated with 10 μg/mL LPS 
(lipopolysaccharide). Activation-induced changes in mean fluorescence were measured in real 
time using a Perkin-Elmer LS55 Spectrofluorometer with excitation at 502 nm and emission at 
523 nm for 15 min. The data are presented as fluorescence intensity of the 523 nm emission over 
time. All experiments were performed in triplicate. The ROS inhibition was defined as the 
percentage of the loss of DCF fluorescence when treated with liposome samples relative to the 
fluorescence intensity of untreated ones. Separate experiments were performed to ensure that the 
liposomal fullerenes do not interfere with the indicator dye in terms of the intensity of 
fluorescent signals. 
 
Results and Discussion 
 
Synthesis. Scheme 1 shows the synthesis of amphiphilic C70 compound ALM. The hydrophilic 
and hydrophobic groups are introduced to C70 through two-step cyclopropanation reactions of 
respective malonates under typical Bingel-Hirsch conditions in high yield (26, 27). Di(tert-
butylglycolate)malonate 3 was prepared from malonic acid and tert-butylbromoacetate in the 
presence of TEA (triethylamine) in 1,4-dioxane at room temperature for 2−3 days. After solvents 
were evaporated, two-phase extraction (water and chloroform) yielded pure compound 3 in 85% 
yield. C70 monoadduct 2 was synthesized in 80% yield by reacting C70and 
didodecylmalonate 1 and purified with silica gel column. Compound 2 then underwent the 
second cyclopropanation reaction with malonate 3 to produce the protected precursor of ALM, 
which was subsequently treated with 30% TFA (trifluoroacetic acid) in DCM to deprotect 
the tert-butyl esters and produce the amphiphilic compound ALM (22). Both ALM and its tert-
butyl ester precursor were fully characterized by NMR, MALDI-MS, FT-IR, and UV−vis 
absorption spectroscopy. In addition, we have demonstrated that the three regioisomers of the 
C70 bisadduct ALM could be separated by reverse-phase HPLC (0.1% TFA in ethanol, C6-
phenyl column; Supporting Information Figure S1), and the structure of each of the three peaks 
in the HPLC chromatogram was assigned based on their polarity and distinct UV−vis absorption 
in the range 350−600 nm (18). This general synthetic approach can be used to prepare a variety 
of amphiphilic C70 compounds, simply by replacing its glycolic acid residues with other polar 
groups. 
 
 
Scheme 1. Synthesis of Amphiphilic Fullerene C70 ALM (the ALM Structure Represents Three 
Isomers) 
 
Liposome Preparation. ALM was first formulated in liposomes with egg-PC (l-α-
phosphatidylcholine) by the reverse-phase method, and the resulting suspension was extruded to 
obtain small vesicles (28, 29). 31P NMR spectroscopy confirmed the formation of bilayer 
liposomes and 31P spectrum of ALM-PC liposome (1 mg/mL ALM) shows a very sharp signal at 
2.55 ppm, with a half line-width of 2.8 Hz, which is comparable to the corresponding values of 
liposomes made of only egg-PC (Supporting Information Figure S2) (30). The particle sizes of 
extruded (with 0.1 μm polycarbonate nucleopore membrane) liposomes were confirmed by DLS 
with an average diameter of 100 ± 20 nm (31). Intriguingly, the fullerene liposomes were 
dimensionally very stable. The amphipathic fullerene did not separate from the phospholipids 
during and after nucleopore extrusion. This was confirmed by buoyant density separation test 
under conditions (high-speed centrifugation at 18 000 g for 30 min.) where fullerenes not stably 
incorporated in bilayer membranes would separate from lipid vesicles and precipitate to the 
bottom of the 40% sucrose cushion. All fullerenes were found to stay on the top of sucrose 
solution after centrifugation, indicating that they remained tightly associated with lipids 
(Supporting Information Figure S3). The tight association between ALM and PC lipids was 
further confirmed by the observed coelution of ALM and egg-PC on a size exclusion column. 
The fact that ALM only did not form liposome and it needs the assistance of regular lipids to 
coassemble into liposomes also demonstrates the successful incorporation of ALM molecule in 
the bilayer structure formed by the auxiliary lipids (Supporting Information Figure S4). In fact, 
the ALM−liposome is stable for at least one year without noticeable precipitation or aggregation. 
The chemical stability of the fullerene compound in liposome formulations was also monitored 
by MALDI-MS, UV−vis, and HPLC after extracting fullerenes into organic solvents from 
aliquots of liposome samples, showing no decomposition or other structural changes. Next, we 
examined the ratio of fullerenes to lipids in the course of forming stable liposome and found that 
fullerene-to-lipid molar ratio could be as high as 1:1 (or mass ratio of roughly 2:1 or 65% 
fullerenes). In typical preparations, the fullerene concentration is 1.0 mg/mL liposome in 
phosphate buffered saline. ALM was also demonstrated to form liposomes in a similar fashion 
with other lipids such as 1,2-dimyristoyl-sn-glycero-3-phosphocholine) (DMPC) and (1,2-
distearoyl-sn-glycero-3-phosphocholine) (DSPC). 
 
EPR Studies. Electron paramagnetic resonance (EPR) studies were conducted as described by 
Ali et al (25) to confirm that bipolarly functionalized C70 compounds were still capable of 
efficiently scavenging oxygen radicals (hydroxyl and superoxide radicals). Representative EPR 
spectra (Figure 2, insert) show typical HO· signals, as well as their quenching by ALM at four 
different concentrations. Figure 2 also shows the dose−response curve of hydroxyl radical-
quenching by ALM solution in DMSO. As expected, ALM is a highly potent scavenger for 
hydroxyl radicals, significantly reducing HO· 4-fold at 10 μg/mL (6.7 µM). ALM also 
effectively quenched superoxide radicals to a slightly lesser extent. It is noteworthy to point out 
that ALM, due to its amphipathic nature, forms micelles in the assay media, and its antioxidative 
efficacy might be partially masked due to its limited access and interaction with free radicals 
generated in the media. 
 
 
Figure 2. Hydroxyl radical quenching by ALM at four different concentrations. Insert shows 
EPR spectra of hydroxyl radicals generated via the Fenton reaction, with (top 4 curves) or 
without (bottom curve) the addition of a DMSO solution of ALM (LnW-0059) at 0.01 mg/mL, 
0.03 mg/mL, 0.05 mg/mL, and 0.11 mg/mL. All observed signals were mixtures of DMPO−OH 
+ DMPO−Me (Fenton products). (The DMPO-Me signal is attributable to radical reactions with 
DMSO). 
 
Protection of Lipid Peroxidation. When lipid molecules, especially unsaturated lipids in cell 
membrane, are exposed to radicals such as hydroxyl radicals, highly reactive lipid species (lipid 
alkyl radicals and lipid peroxy radicals) are formed and the resulting lipid peroxidation can 
eventually cause membrane leakage and cellular dysfunction (32). Fullerenes formulated in 
liposome vesicles are particularly attractive for inhibiting lipid peroxidation. The protection 
effects of ALM liposome on hydroxyl radical-induced lipid peroxidation were therefore 
evaluated. The hydroxyl radicals were generated by the Fenton reaction as described above. A 
pH-sensitive dye 8-hydroxylpyrene-1,3,6-trisulfonic acid trisodium salt (HPTS) was 
encapsulated in the internal aqueous compartment of ALM−liposome and control liposome 
(without ALM) with a lower pH of 6.6 (23, 24). The outer bulk aqueous phase has a higher pH of 
7.9. Upon membrane leakage caused by lipid peroxidation, the dye absorption ratio A455 nm/A405 
nm increases due to the rising pH, and a higher ratio A455 nm/A405 nm indicates a greater extent of 
membrane leakage and lipid peroxidation. Fullerenes have strong absorption in the range 
400−450 nm; thus, the ALM content was kept very low at 1% to clearly monitor the spectral 
changes of the dye. In order to explicitly demonstrate the protection effects, both absorbance 
ratio (A455 nm/A405 nm) and absorbance difference (A455 nm − A405 nm) were plotted as a function of 
time (t = 0 when HO· generation reaction was initiated) (Figure 3). The membrane leakage in the 
control liposome was dramatic, but it was minimal in the ALM−liposome sample. Additional 
control experiments were also conducted, and the A455 nm/A405 nm of HPTS was monitored in 
ALM−liposome or control liposome samples in the absence of the Fenton reagents. No 
noticeable changes in the absorption spectra of HPTS were observed for both samples, excluding 
the possibility that the control liposome is inherently leakier than the ALM-encapsulated 
liposome. These results clearly demonstrate the strong protection effects of ALM liposome 
against radical-induced peroxidation and membrane leakage. 
 
 
Figure 3. Absorbance ratio (A455 nm/A405 nm, top) and absorbance difference (A455 nm − A405 nm, 
bottom) of HPTS as a function of reaction time from when the Fenton reagents were added to the 
liposome samples. 1% fullerene was contained in ALM liposome. (1.0 mM H2O2and 0.05 mM 
Fe2+ ions of final concentrations). 
 
In Vitro ROS Inhibition and Cytotoxicity. ALM liposome was also evaluated for its capability 
to quench extra cellular reactive oxygen species (ROS) release triggered by lipopolysaccharide 
(LPS) (33, 34). The monocyte cell line U937 used in this study is clinically relevant to 
atherosclerosis. The generation of foam cells from activated monocytes involves ROS 
overproduction and is a key inflammatory process in atherosclerotic plaque buildup (35). U937 
monocytes, before LPS activation, were treated with a cell-permeable fluorogenic probe 2′,7′-
dichlorodihydrofluorescein diacetate (DCFH-DA) (36). Following LPS activation, DCFH-DA 
underwent cellular hydrolysis and oxidation by ROS to generate the highly fluorescent 2′,7′-
dichlorofluorescein (DCF). As shown in Figure 4, ALM liposome inhibited cellular ROS release, 
while the control liposome (without ALM) did not. More than 80% ROS release was inhibited 
when the cells were treated with 6 μM ALM liposome samples, and even at 6 nM, the inhibition 
was over 20%. This suggests that the liposome formulation efficiently delivered amphiphilic 
fullerenes into cells and effectively exerted its anti-ROS efficacy. The liposomal ALM was also 
compared with a well-studied water-soluble C60 derivative-C3 (six carboxyl groups—three 
malonic acids directly attached to a C60 cage) in this assay (9). As shown in Figure 4, ALM was 
40−70% more potent than C3 in scavenging cellular ROS when compared at equal molar 
concentrations. This could be explained by the difference in their dipole moments, structural 
dimension, and the resultant ability to intercalate in lipid bilayer and permeate cell membranes. 
Amphiphilic fullerene ALM has higher lipid/aqueous partition coefficient than C3 in favor of 
cellular membrane permeation in addition to the potential endocytotic uptake of ALM liposome. 
 
 
Figure 4. Inhibition of ROS in U937 monocytes by liposomes. For each concentration, the same 
volume of control liposome was used as the control. The fluorescence intensity was recorded and 
used as the measure to quantify ROS inhibition. 
 
Finally, the cytotoxicity of the ALM liposome was examined. A number of factors including 
chemical structure, surface modification, water solubility, aggregation, particle size, and 
preparation procedures appear to have impacts on fullerene toxicity and behavior in biological 
systems (11, 37). In general, well-characterized fullerene derivatives with high solubility in 
buffer have little or no toxicities. We evaluated the cytotoxicity of ALM liposome with U937 
monocytes, and ALM was found not cytotoxic to U937 cells when incubated with up to 67 μM 
(0.1 mg/mL) of ALM for 6 days. The cell viabilities were comparable for ALM-treated, vitamin 
E-treated, and untreated cells at all concentrations (Supporting Information Figure S5). 
 
Conclusions 
 
We have presented a novel fullerene delivery approach via liposomes enriched with amphiphilic 
C70 bisadducts that were designed to structurally mimic cellular membrane lipids. The choice of 
C70 along with its inherent bipolar bisaddition pattern represents a novel pathway to design 
amphiphilic fullerene compounds compatible for vesicular incorporation. The strong association 
between reported fullerenes and auxiliary lipids allow them to form dimensionally stable 
liposomes with as high as 65% (by weight) fullerene. By mimicking the structure of naturally 
occurring lipid molecules, this design overcomes several limitations in previously reported 
formulations including (1) low fullerene content of 3%−7% due to their use of underivatized 
C60(12, 13) or lipophilically functionalized C60(38), structures of which are not dimensionally 
compatible with the polar head/lipophilic double-tail structure of lipids; and (2) damaged 
antioxidative bioactivity due to the multiple additions of six groups to C60 in an octahedral 
pattern where the spherical π-electron conjugation is interrupted leading to interconnected 
biphenyls (16, 39). As a drug delivery vehicle, the high fullerene loading capacity is very 
important, and it is advantageous especially for in vivo studies such as the delivery of fullerene 
to its intended region of action at sufficient concentrations with lower dose volumes. The 
vesicularly formulated fullerene ALM has been demonstrated as potent radical scavengers in 
three separate ROS-related experiment settings. In summary, this present approach provides a 
new way to deliver fullerenes to sites where their antioxidant properties can be exploited and 
provides a platform for synthesizing new fullerene-based therapeutics that not only retain their 
biological activity, but can also be delivered via liposome carriers. 
 
Supporting Information 
 
Additional information as described in the text and mass spectra. This material is available free 
of charge via the Internet at http://pubs.acs.org. 
 
Acknowledgment 
 
This work was partially supported by NIH Grants 1R01GM083274-01 and 1R43HL087578-
01A1 (CLK). We thank Dr. Anthony Ribeiro at Duke NMR Center for assistance in acquiring 
the 31P NMR spectrum. 
 
References 
1. Krustic, P. J., Wasserman, E., Keizer, P. N., Morton, J. R., and Preston, K. F. (1991) Radical 
reactions of C60Science 254, 1183– 1185 
2. Partha, R. and Conyers, J. L. (2009) Biomedical applications of functionalized fullerene-
based nanomaterialsInt. J. Nanomed. 4, 261– 275 
3. Bosi, S., Da Ros, T., Spalluto, G., and Prato, M. (2003) Fullerene derivatives: an attractive 
tool for biological applications Eur. J. Med. Chem. 38, 913– 923 
4. Nakamura, E. and Isobe, H. (2003) Functionalized fullerenes in water. The first 10 years of 
their chemistry, biology, and nanoscience Acc. Chem. Res. 36, 807– 815 
5. Jensen, A. W., Wilson, S. R., and Schuster, D. I. (1996) Biological applications of 
fullerenes Bioorg. Med. Chem.4, 767– 779 
6. Tsai, M. C., Chen, Y. H., and Chiang, L. Y. (1997) Polyhydroxylated C60, fullerenol, a novel 
free-radical trapper, prevented hydrogen peroxide- and cumene hydroperoxide-elicited 
changes in rat hippocampus in-vitro J. Pharm. Pharmacol. 49, 438– 445 
7. Husebo, L. O., Sitharaman, B., Furukawa, K., Kato, T., and Wilson, L. J. (2004) Fullerenols 
revisited as stable radical anions J. Am. Chem. Soc. 126, 12055– 12064 
8. Huang, S. S., Tsai, S. K., Chih, C. L., Chiang, L. Y., Hsieh, H. M., Teng, C. M., and Tsai, M. 
C. (2001)Neuroprotective effect of hexasulfobutylated C60 on rats subjected to focal cerebral 
ischemia Free Radic. Biol. Med. 30, 643– 649 
9. Dugan, L. L., Turetsky, D. M., Du, C., Lobner, D., Wheeler, M., Almli, C. R., Shen, C. K.-
F., Luh, T.-Y., Choi, D. W., andLin, T.-S. (1997) Carboxyfullerenes as neuroprotective 
agents Proc. Natl. Acad. Sci. U.S.A. 94, 9434–9439 
10. Brettreich, M. and Hirsch, A. (1998) A highly water-soluble dendro[60]fullerene Tetrahedron 
Lett. 39, 2731–2734 
11. Johnston, H. J., Hutchison, G. R., Christensen, F. M., Aschberger, K., and Stone, 
V. (2010) The biological mechanisms and physicochemical characteristics Responsible for 
driving fullerene toxicity Toxicol. Sci. 114,162– 182 
12. Bensasson, R. V., Bienvenue, E., Dellinger, M., Leach, S., and Seta, P. J. (1994) C60 in 
model biological systems. A visible-UV absorption study of solvent-dependent parameters 
and solute aggregation J. Phys. Chem. 98, 3492–3496 
13. Hungerbuhler, H., Guldi, D. M., and Asmus, K. D. (1993) Incorporation of C60 into artificial 
lipid membranes J. Am. Chem. Soc. 115, 3386– 3390 
14. Ikeda, A., Doi, Y., Hashizume, M., Kikuchi, J., and Konishi, T. (2007) An extremely 
effective DNA photocleavage utilizing functionalized liposomes with a fullerene-enriched 
lipid bilayer J. Am. Chem. Soc. 129, 4140– 4141 
15. Kato, S., Kikuchi, R., Aoshima, H., Saitoh, Y., and Miwa, N. (2010) Defensive effects of 
fullerene-C60/liposome complex against UVA-induced intracellular reactive oxygen species 
generation and cell death in human skin keratinocytes HaCaT, associated with intracellular 
uptake and extracellular excretion of fullerene-C60 J. Photochem. Photobiol. B 98, 144– 151 
16. Brettreich, M., Burghardt, S., Bottcher, C., Bayerl, T., Bayerl, S., and Hirsch, 
A. (2000) Globular amphiphiles: Membrane-forming hexaadducts of C60 Angew. Chem., Int. 
Ed. 39, 1845– 1848 
17. Maierhofer, A. P., Brettreich, M., Burghardt, S., Vostrowsky, O., Hirsch, A., Langridge, S., 
and Bayerl, T. M. (2000)Structure and electrostatic interaction properties of monolayers of 
amphiphilic molecules derived from C60-fullerenes: A film balance, neutron, and infrared 
reflection study Langmuir 16, 8884– 8891 
18. Herrmann, A., Rüttimann, M., Thilgen, C., and Diederich, A. (1995) Multiple 
Cyclopropanations of C70. Synthesis and characterization of bis-, tris-, and tetrakis-adducts 
and chiroptical properties of bis-adducts with chiral addends, including a recommendation 
for the configurational description of fullerene derivatives with a chiral addition pattern Helv. 
Chim. Acta 78, 1673– 1704 
19. Gan, L., Huang, S., Zhang, X., Zhang, A., Cheng, B., Cheng, H., Li, X., and Shang, 
G. (2002) Fullerenes as a tert-butylperoxy radical trap, metal catalyzed reaction of tert-butyl 
hydroperoxide with fullerenes, and formation of the first fullerene mixed peroxides J. Am. 
Chem. Soc. 124, 13384– 13385 
20. Birkett, P. R., Avent, A. G., Darwish, A. D., Kroto, H. W., Taylor, R., and Walton, D. R. 
M. (1995) Formation and characterization of C70Cl10 J. Chem. Soc., Chem. 
Commun. 683– 684 
21. Scuseria, G. E. (1991) The equilibrium structure of C70. An ab initio Hartree-Fock 
study Chem. Phys. Lett. 180,451– 469 
22. Zhou, Z., Schuster, D. I., and Wilson, S. R. (2003) Selective syntheses of novel polyether 
fullerene multiple adducts J. Org. Chem. 68, 7612– 7617 
23. Kano, K. and Fendler, J. H. (1978) Pyranine as a sensitive pH probe for liposome interiors 
and surfaces. pH gradients across phospholipid vesicles Biochim. Biophys. 
Acta 509, 289– 296 
24. Wang, C., Tai, L. A., Lee, D. D., Kanakamma, P. P., Shen, C., K. F., Luh, T. Y., Cheng, C. 
H., and Hwang, K. C.(1999) C60 and water-soluble fullerene derivatives as antioxidants 
against radical-initiated lipid peroxidation J. Med. Chem. 42, 4614– 4620 
25. Ali, S. S., Hardt, J. I., Quick, K. L., Kim-Han, J. S., Erlamger, B. F., Huang, T. T., Epstein, 
C. J., and Dugan, L. L.(2004) A biologically effective fullerene C60 derivative with 
superoxide dismutase mimetic properties Free Radic. Biol. Med. 37, 1191– 1202 
26. Bingel, C. (1993) Cyclopropylation of fullerenes Chem. Ber. 126, 1957– 1958 
27. Zhou, Z. and Wilson, S. R. (2005) Tether-directed multiple functionalization of 
fullerene[60] Curr. Org. Chem. 9,789– 811 
28. Pidgeon, C., McNeely, S., Schmidt, T., and Johnson, J. E. (1987) Multilayered vesicles 
prepared by reverse-phase evaporation: liposome structure and optimum solute 
entrapment Biochemistry 26, 17– 29 
29. Gruner, S. M., Lenk, R. P., Janoff, A. S., and Ostro, M. J. (1985) Novel multilayered lipid 
vesicles: comparison of physical characteristics of multilamellar liposomes and stable 
plurilamellar vesicles Biochemistry 24, 2833–2842 
30. Berden, J. A., Cullis, P. R., Hoult, D. I., McLaughlin, A. C., Radda, G. K., and Richards, R. 
E. (1974) Frequency dependence of 31P NMR linewidths in sonicated phospholipid vesicles: 
effects of chemical shift anisotropy FEBS Lett. 46, 55– 58 
31. Winterhalter, M. and Lasic, D. D. (1993) Liposome stability and formation: experimental 
parameters and theories on the size distribution Chem. Phys. Lipids 64, 35– 43 
32. Niki, E. (2009) Lipid peroxidation: physiological levels and dual biological effects Free 
Radic. Biol. Med. 47,469– 484 
33. Stocker, R. and Keaney, J. F. (2004) Role of oxidative modifications in 
atherosclerosis Physiol. Rev. 84, 1381–1478 
34. Aviram, M. (1999) Macrophage foam cell formation during early atherogenesis is 
determined by the balance between prooxidants and antioxidants in arterial cells and blood 
lipoproteins Antioxid. Redox. Signal. 1, 585–594 
35. Schwartz, C. J., Kelley, J. L., Nerem, R. M., Sprague, E. A., Rozek, M. M., Valente, A. 
J., Edwards, E. H., Prasad, A. R., Kerbacher, J. J., and Logan, S. A. (1989) Pathophysiology 
of the atherogenic process Am. J. Cardiol. 64,23G– 30G 
36. Rosenkranz, A. R., Schmaldienst, S., Stuhlmeier, K. M., Chen, W., Knapp, W., 
and Zlabinger, G. J. (1992) A microplate assay for the detection of oxidative products using 
2′,7′-dichlorofluorescin-diacetate J. Immunol. Methods 156, 39– 45 
37. Kolosnjaj, J., Szwarc, H., and Moussa, F. (2007) Toxicity studies of fullerenes and 
derivatives Adv. Exp. Med. Biol. 620, 168– 180 
38. Lens, M., Medenica, L., and Citernesi, U. (2008) Antioxidative capacity of C-60 
(buckminsterfullerene) and newly synthesized fulleropyrrolidine derivatives encapsulated in 
liposomes Biotechnol. Appl. Biochem. 51, 135–140 
39. Partha, R., Lackey, M., Hirsch, A., Casscells, S. W., and Conyers, J. L. (2007) Self assembly 
of amphiphilic C60 fullerene derivatives into nanoscale supramolecular structures J. 
Nanobiotechnol. 5:6, 1– 11 
 
